Drug Trial Radar · NCT03081949
Peripartum Cardiomyopathy in Nigeria Registry
Last checked: Nov 20, 2026Latest source record: Jan 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
100
Actual
Start
Jun 12, 2017
Primary completion
Jun 30, 2019
Study completion Dec 31, 2019
Sponsor
- Lead sponsor
- Aminu Kano Teaching HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Nigerian Cardiac Society
- First posted
- Mar 17, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Peripartum cardiomyopathy (PPCM) is a global disease with significant morbidity and mortality, and Nigeria probably has the highest burden of the disease in the world. Unfortunately, much about the disease including its aetiology, epidemiology and treatment is not yet well described. This will be a prospective, national, multicenter cohort study, conducted in centres in Nigeria. It is expected that approximately 500 patients with PPCM and 500 apparently healthy pregnant women will be recruited over a 6-month period with follow-up at 3-monthly intervals for 18 months.
Conditions
- Peripartum Cardiomyopathy
Interventions
Oral Sodium Selenite 200 µg/day for 3 monthsDrug
PPCM patients with selenium deficiency, who have not achieved LV reverse remodelling (LVRR) (LV end-diastolic dimension indexed to body surface area (LVEDDi) ≤33.0 mm/m2) at 6 months after diagnosis.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Prevalence of peripartum cardiomyopathy (PPCM) in NigeriaTime frame: Over 6 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Aminu Kano Teaching Hospital
Kano, Nigeria
Aminu Kano Teaching Hospital
Kano, Nigeria
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.